AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05950373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education video
Description: six minute long education video focusing on protein and energy meals for older adults.
Study NCT05791487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis Exclusion Diet
Description: a limited whole food diet (UCED)
Study NCT05791487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial enteral nutrition (PEN)
Description: The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles.
Study NCT04814576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative cares
Description: The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
Study NCT05282173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siyakhana CHW Training
Description: Please see arm description.
Study NCT05747729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib and Serplulimab
Description: Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks.
Study NCT04612556 — intervention group
Intervention type: DRUG
Intervention: Mepolizumab 100 MG [Nucala]
Description: subcutaneous injection once a month
Study NCT05791487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free diet
Description: oral Budeosnide for 6 weeks + free diet
Study NCT05791487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Budesonide
Description: Oral Budesonide 9 mg
Study NCT05542264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
Study NCT05542264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study NCT04558918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
Study NCT04558918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Study NCT05791487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide
Description: Oral Budesonide 9 mg
Study NCT05457673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor StealthTrac Lead
Description: Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
Study NCT04656145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing
Description: On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
Study NCT05347550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings - Thromboembolic deterrent stockings
Description: Centres randomised to the intervention arm will consist of participants receiving GCS.
Study NCT05725850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EG (Experimental A. Oleracea extract gel)
Description: Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
Study NCT05725850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GP (Gel placebo)
Description: Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
Study NCT05387655 — intervention group
Intervention type: BIOLOGICAL
Intervention: BCG
Description: BCG vaccination
Study NCT05387655 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placebo vaccine
Description: Placebo vaccination
Study NCT04558918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Study NCT04804410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCR Meter (Brand: Keysight, Serial Number:E498AL)
Description: The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
Study NCT05747092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gingival graft
Description: investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope
Study NCT05747092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gingival graft
Description: investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope
Study NCT06454110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
Study NCT04718467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
Study NCT04718467 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
Study NCT05052385 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib
Description: As per treating physician's decision - non interventional study
Study NCT05052385 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: As per treating physician's decision - non interventional study
Study NCT05052385 — intervention group
Intervention type: DRUG
Intervention: Ibrutinib
Description: As per treating physician's decision - non interventional study
Study NCT05795647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline+Tocopherol
Description: Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
Study NCT06136000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sacral erectör spinae plane block
Description: Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
Study NCT06136000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ring Block
Description: The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
Study NCT05390879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: After the circuit, a 6 minutes long meditation auto-guided video.
Study NCT05390879 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: After the circuit, a 6 minutes long emotionally neutral video.
Study NCT06238232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor PET/CT
Description: The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
Study NCT05864560 — intervention group
Intervention type: DEVICE
Intervention: Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System
Description: Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
Study NCT05891509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Hematoma Evacuation
Description: Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
Study NCT05891509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Best medical therapy
Study NCT05891509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Medical Therapy
Description: Best medical therapy
Study NCT04698031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Description: After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
Study NCT04698031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Description: After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
Study NCT05543525 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Transthoracic echocardiography
Study NCT05543525 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing
Study NCT06340828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washing Microbiota Transplantation
Description: Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
Study NCT06287528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z/IL-18 CAR T cells
Description: 19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
Study NCT04728061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gen1E-1124
Description: Intravenously-infused Gen1E-1124 in vehicle.
Study NCT04728061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenously-infused vehicle.
Study NCT04832685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound
Study NCT04832685 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound
Study NCT05007977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp
Study NCT05007977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp
Study NCT05595018 — intervention group
Intervention type: OTHER
Intervention: End user
Description: Participants will provide their opinions in two rounds to reach consensus
Study NCT05595018 — intervention group
Intervention type: OTHER
Intervention: Demand side- management
Description: Participants will provide their opinions in two rounds to reach consensus
Study NCT05595018 — intervention group
Intervention type: OTHER
Intervention: Supply side
Description: Participants will provide their opinions in two rounds to reach consensus
Study NCT05595018 — intervention group
Intervention type: OTHER
Intervention: Funder
Description: Participants will provide their opinions in two rounds to reach consensus
Study NCT05595018 — intervention group
Intervention type: OTHER
Intervention: Academia
Description: Participants will provide their opinions in two rounds to reach consensus
Study NCT05953948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent Case Manage Platform (ICMP) and self-management program
Description: This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
Study NCT05938543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS
Study NCT06221514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Core Strengthening Programs
Description: The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions.
Study NCT06221514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder Strengthening Programs
Description: The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions.
Study NCT05255042 — intervention group
Intervention type: OTHER
Intervention: organ and tissue sample collection only
Description: Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
Study NCT05512702 — intervention group
Intervention type: DRUG
Intervention: Tissue Plasminogen Activator, Alteplase
Description: Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
Study NCT05512702 — intervention group
Intervention type: DRUG
Intervention: Low-molecular weight heparin
Description: Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
Study NCT05759468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Product - MIB 626
Description: The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, >75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
Study NCT05759468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Study NCT06162091 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months.
Study NCT05705752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
Study NCT05705752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates training
Description: 12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
Study NCT04845191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
Study NCT06605196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources and guided facilitation
Description: Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
Study NCT06605196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing resources
Description: Individuals will be referred to existing resources in the Learning Community.
Study NCT05731076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management support nutrition and exercise intervention
Description: Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
Study NCT05863923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)
Description: Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
Study NCT05863923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M2Q2-HIV Comparison
Description: Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
Study NCT04971473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
Study NCT05894421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2223 injection+ Penpulimab Injection
Description: TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.